HalioDx: HalioDx

IMMUNOSCORE®

Scoring Immune Response in Colon Cancer

For unmatched clinical performance in routine settings

More info

IMMUNOSCORE® IC

in Non-Small Cell Lung cancer (NSCLC)

Combine PD-L1 with CD8 to improve predictive value of PD-L1

More info

Clinical Research

A new class of Immuno-Oncology Scoring Services

For academic, clinical centers and biopharmaceutical companies

More info

Companion Diagnostic

HalioDx approach to successfully develop CDx

From Biomarker Discovery to CDx development and commercialization

More info

Latest News

& Events

Date: From 2019-05-31 to 2019-06-04
Location: Chicago, USA

Date: From 2019-06-03 to 2019-06-06
Location: Philadelphia, USA

In the media :

Wednesday 20 March 2019 - Spoke: Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio | Spoke | Thursday 14 March 2019 - MyPharma Editions: Transgene : le développement de myvac™ bénéficie d’une aide de 5,2 millions d’euros du Programme d’Investissements d’Avenir | Wednesday 13 March 2019 - Spoke: Transgene - NEOVIVA Project Supporting the Development of myvac™ Awarded a €5.2 Million Grant from Bpifrance’s “Investments for the Future” Programme | Spoke | Wednesday 14 November 2018 - Marseille Immunopole: RT @HalioDx: #Immunoscore Provides Risk Assessments for All Stages of #ColonCancer https://t.co/DjPKMRk2yY @TargetedOnc @JeromeGalon @sitcancer #SitC2018 https://t.co/Jag3zAcAS9 | Sunday 11 November 2018 - HalioDx: #Cancer #Immunotherapy world #NSCLC expert @YaleCancer /“#Biomarkers will be critical... we must personalize it (I-O Tx) to get to optimal effect” #SITC2018 @sitcancer #immunoscore #TAMPP @HalioDx @DefiniensLife @Akoya_Codex_QPS @Incyte @BMS_Immu |